JAZZ Jazz Pharmaceuticals plc

Price (delayed)

$173.93

Market cap

$9.9B

P/E Ratio

18.72

Dividend/share

N/A

EPS

$9.29

Enterprise value

$10.04B

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights
The company's EPS has surged by 117% QoQ and by 89% YoY
Jazz Pharmaceuticals's net income has surged by 117% QoQ and by 85% YoY
Jazz Pharmaceuticals's quick ratio has increased by 15% YoY but it has decreased by 2.3% from the previous quarter
The company's debt rose by 27% YoY

Key stats

What are the main financial stats of JAZZ
Market
Shares outstanding
56.9M
Market cap
$9.9B
Enterprise value
$10.04B
Valuations
Price to earnings (P/E)
18.72
Price to book (P/B)
2.58
Price to sales (P/S)
4.03
EV/EBIT
13.75
EV/EBITDA
9.9
EV/Sales
4.12
Earnings
Revenue
$2.44B
EBIT
$729.69M
EBITDA
$1.01B
Free cash flow
$913.59M
Per share
EPS
$9.29
Free cash flow per share
$16.18
Book value per share
$67.42
Revenue per share
$43.15
TBVPS
$65.7
Balance sheet
Total assets
$6.76B
Total liabilities
$2.96B
Debt
$2.24B
Equity
$3.8B
Working capital
$2.41B
Liquidity
Debt to equity
0.59
Current ratio
4.21
Quick ratio
3.78
Net debt/EBITDA
0.14
Margins
EBITDA margin
41.6%
Gross margin
93.4%
Net margin
21.3%
Operating margin
30%
Efficiency
Return on assets
8.1%
Return on equity
14.8%
Return on invested capital
19.6%
Return on capital employed
12.2%
Return on sales
29.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
0.06%
1 week
-0.84%
1 month
-1.72%
1 year
53.91%
YTD
5.38%
QTD
-2.09%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$2.44B
Gross profit
$2.28B
Operating income
$729.87M
Net income
$518.28M
Gross margin
93.4%
Net margin
21.3%
Jazz Pharmaceuticals's net income has surged by 117% QoQ and by 85% YoY
The company's net margin has surged by 111% QoQ and by 66% YoY
The operating income has surged by 93% since the previous quarter
JAZZ's operating margin has soared by 88% since the previous quarter

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
P/E
18.72
P/B
2.58
P/S
4.03
EV/EBIT
13.75
EV/EBITDA
9.9
EV/Sales
4.12
The company's EPS has surged by 117% QoQ and by 89% YoY
The P/E is 49% lower than the last 4 quarters average of 36.7 and 17% lower than the 5-year quarterly average of 22.5
Jazz Pharmaceuticals's equity has increased by 35% YoY and by 3.8% from the previous quarter
The price to book (P/B) is 14% lower than the 5-year quarterly average of 3.0 but 12% higher than the last 4 quarters average of 2.3
The price to sales (P/S) is 15% more than the last 4 quarters average of 3.5 but 10% less than the 5-year quarterly average of 4.5
The revenue has grown by 11% YoY and by 3.1% from the previous quarter

Efficiency

How efficient is Jazz Pharmaceuticals business performance
JAZZ's ROIC has soared by 168% YoY and by 90% QoQ
The company's return on assets has surged by 103% QoQ and by 56% YoY
The return on equity has surged by 103% since the previous quarter and by 57% year-on-year
The company's return on sales has surged by 90% QoQ

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 128% greater than the total liabilities
The total assets is up by 30% year-on-year and by 3.4% since the previous quarter
JAZZ's total liabilities is up by 23% year-on-year and by 2.9% since the previous quarter
The company's debt is 41% lower than its equity
Jazz Pharmaceuticals's equity has increased by 35% YoY and by 3.8% from the previous quarter
The company's debt rose by 27% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.